Taghvaei, R., Zadeh, M. Z., Sirous, R., Shamchi, S. P., Raynor, W. Y., Seraj, S. M., . . . Alavi, A. (2018). Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing/refractory non-hodgkin lymphoma following radioimmunotherapy. Am J Nucl Med Mol Imaging.
Style de citation ChicagoTaghvaei, Raheleh, et al. "Pre-treatment Partial-volume-corrected TLG Is the Best Predictor of Overall Survival in Patients With Relapsing/refractory Non-hodgkin Lymphoma Following Radioimmunotherapy." Am J Nucl Med Mol Imaging 2018.
Style de citation MLATaghvaei, Raheleh, et al. "Pre-treatment Partial-volume-corrected TLG Is the Best Predictor of Overall Survival in Patients With Relapsing/refractory Non-hodgkin Lymphoma Following Radioimmunotherapy." Am J Nucl Med Mol Imaging 2018.